In preparation for the World Orphan Drug Congress 2012, we collated a representative summary of the responses gained from our industry survey. We opened the survey up to a senior executive selection of the global orphan and rare disease market onwards of May 2012.
What follows are viewpoints and opinions from approx. 375 international biopharmaceutical stakeholders from across Europe and North America.
The views made in this document have been used to structure and develop the 2012 3rd Annual World Orphan Drug Congress from 29-30 November 2012 in Geneva, the region’s largest gathering for the full stakeholder network and rare disease KOLs.